Cited by 460Rheumatoid Arthritis Research and TherapiesImmunodeficiency and Autoimmune DisordersT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Bingham, Clifton O., Looney, R. John, Deodhar, Atul, Halsey, Neal, Greenwald, Maria, Codding, Christine, Trzaskoma, Benjamin, Martin, Flavius, Agarwal, Sunil, Kelman, Ariella·2010·Arthritis & Rheumatism

DOI 10.1002/art.25034

Open this paper in CoChat — free account

Abstract

Objective: To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab‐induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell–dependent antigen), pneumococcal polysaccharide (T cell–independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed‐type hypersensitivity (DTH). Methods: In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab‐treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4‐fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti‐KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2–3 days following placement. Results: Responses to tetanus toxoid vaccine (≥4‐fold rise) were similar in both groups (39.1% of rituximab‐treated patients and 42.3% of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4% of rituximab‐treated patients and 70% of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab‐treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2‐fold rise in titer in response to ≥1 serotype, compared with 82% of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti‐KLH IgG, compared with 93% of patients treated with MTX alone). Conclusion: Recall responses to the T cell–dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab‐treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell–independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.

Integrity signals

Registry

Crossref · 10.1002/art.25034

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citation
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Cohen, S. B., Emery, P., Greenwald, M., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., LOVELESS, J. E., Burmester, G. R., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citation
Characterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R., Li, N. F., Agarwal, S. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,061
Self-citation
Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 999
Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups
Robbins, J. B., AUSTRIAN, R. C., Lee, C. J., Rastogi, S. C., Schiffman, G., Henrichsen, J., Mäkelä, P. H., Broome, C. V., Facklam, R. R., Tiesjema, R. H., et al. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/148.6.1136 · Cited by 565
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L. J., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 542
Self-citation
Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice
DiLillo, D. J., Hamaguchi, Y., Ueda, Y., Yang, K., Uchida, J., Haas, K. M., Kelsoe, G. H., & Tedder, T. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.361 · Cited by 397
Keyhole limpet hemocyanin (KLH): a biomedical review
Harris, J. R., & Markl, J. (1999) · Micron · doi:10.1016/s0968-4328(99)00036-0 · Cited by 376

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

2008, Pneumovax package insert
Galazka A, The Immunological Basis for Immunization Series Module 3: Tetanus
Handwerger B, 2004, Effects of Anakinra (KINERET) on vaccine response in patients with rheumatoid arthritis, Arthritis Rheum, 50, S564

Sorted by citations

Items 101–200 of 460

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines
Tieu, J., Smith, R., Basu, N., Brogan, P. A., D’Cruz, D. P., Dhaun, N., Floßmann, O., Harper, L., Jones, R. B., Lanyon, P., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez640 · Cited by 67
Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children
Davies, H. D., Byington, C. L., Maldonado, Y., Barnett, E. D., Edwards, K. M., Lynfield, R., Muñoz, F. M., Nolt, D. L., Nyquist, A., Rathore, M. H., et al. (2016) · PEDIATRICS · doi:10.1542/peds.2016-1209 · Cited by 66
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Houot, R., Levy, R., Cartron, G., & Armand, P. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.017 · Cited by 59
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions
Bennett, C. L., Focosi, D., Socal, M. P., Bian, J., Nabhan, C., Hrushesky, W. J. M., Bennett, A. C., Schoen, M. W., Berger, J. R., & Armitage, J. O. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00167-8 · Cited by 65
Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens
Bar‐Or, A., Wiendl, H., Miller, B., Bénamor, M., Truffinet, P., Church, M., & Menguy-Vacheron, F. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000070 · Cited by 65
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement
Riva, A., Barcella, V., Benatti, S. V., Capobianco, M. A. N., Capra, R., Cinque, P. M., Comi, G., Fasolo, M., Franzetti, F., Galli, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520952310 · Cited by 66
Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys
Vaidyanathan, A., McKeever, K., Anand, B. S., Eppler, S., Weinbauer, G. F., & Beyer, J. C. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq316 · Cited by 64
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
Winthrop, K. L., Bingham, C. O., Komocsar, W. J., Bradley, J., Issa, M., Klar, R., & Kartman, C. E. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1883-1 · Cited by 61
Self-citation
COVID-19 vaccination in immunocompromised patients
Sonani, B., Aslam, F., Goyal, A., Patel, J., & Bansal, P. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05547-w · Cited by 64
Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment
Bijl, M., Agmon‐Levin, N., Dayer, J.-M., Israeli, E., Gatto, M., & Shoenfeld, Y. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.015 · Cited by 62
Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
Kim, W., Kim, S. H., Huh, S., Kong, S., Choi, Y. J., Cheong, H. J., & Kim, H. J. (2013) · European Journal of Neurology · doi:10.1111/ene.12132 · Cited by 62
Vaccines and Disease-Modifying Antirheumatic Drugs
Friedman, M., & Winthrop, K. L. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.003 · Cited by 60
Suppression of normal immune responses after treatment with rituximab
Kado, R., Sanders, G., & McCune, W. J. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000272 · Cited by 60
Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)
Nguyen, M., Lindegaard, H., Hendricks, O., & Friis‐Møller, N. (2017) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2016.1242774 · Cited by 60
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series
Connolly, C. M., Boyarsky, B. J., Ruddy, J. A., Werbel, W. A., Christopher‐Stine, L., Garonzik‐Wang, J., Segev, D. L., & Paik, J. J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1451 · Cited by 59
Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial
Desai, S. P., Lü, B., Szent‐Gyorgyi, L. E., Bogdanova, A. A., Turchin, A., Weinblatt, M. E., Coblyn, J. S., Greenberg, J. O., Kachalia, A. B., & Solomon, D. H. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37716 · Cited by 59
Impact of rituximab on COVID-19 outcomes
Levavi, H., Lancman, G., & Gabrilove, J. L. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04662-1 · Cited by 58
Infections and Biologic Therapy in Rheumatoid Arthritis
Winthrop, K. L. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.08.019 · Cited by 64
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
Rempe, T. J., & Harel, A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102341 · Cited by 57
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 64
Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
Worch, J., Makarova, O., & Burkhardt, B. (2015) · Cancers · doi:10.3390/cancers7010305 · Cited by 57
Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic
Krasselt, M., Ivanov, J.-P., Baerwald, C., & Seifert, O. (2016) · Rheumatology International · doi:10.1007/s00296-016-3608-y · Cited by 57
Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases
Wijetilleka, S., Jayne, D. R. W., Mukhtyar, C. B., Ala, A., Bright, P., Chinoy, H., Harper, L., Kazmi, M. A., Kiani‐Alikhan, S., Li, C. K., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key394 · Cited by 56
Complications of long-term therapy for ANCA-associated systemic vasculitis
Wall, N. A., & Harper, L. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.107 · Cited by 55
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation
Lebrec, H. N., Molinier, B., Boverhof, D. R., Collinge, M., Freebern, W. J., Henson, K. L., Mytych, D. T., Ochs, H. D., Wange, R. L., YANG, Y. G., et al. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.02.008 · Cited by 55
Rituximab for immunologic renal disease: What the nephrologist needs to know
Kronbichler, A., Windpessl, M., Pieringer, H., & Jayne, D. R. W. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.007 · Cited by 55
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
Walti, C. S., Loes, A. N., Shuey, K. D., Krantz, E. M., Boonyaratanakornkit, J. B., Keane-Candib, J., Loeffelholz, T., Wolf, C. R., Taylor, J. J., Gardner, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003428 · Cited by 57
Infectious complications of rituximab therapy in renal disease
Nixon, A. C., Ogden, L., Woywodt, A., & Dhaygude, A. P. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx038 · Cited by 54
The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy
Hale, M. R., Rawlings, D. J., & Jackson, S. W. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.10.008 · Cited by 53
Good and bad memories following rituximab therapy
Clair, E. W. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25039 · Cited by 51
Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und Empfehlungen
Wiedermann, U., Sitte, H. H., Burgmann, H., Eser, A., Falb, P., Holzmann, H., Kitchen, M., Köller, M. D., Kollaritsch, H., Kundi, M., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-1033-6 · Cited by 51
A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus
Chatham, W. W., Chadha, A., Fettiplace, J., Kleoudis, C. S., Bass, D., Roth, D. A., & Gordon, D. N. (2017) · Lupus · doi:10.1177/0961203317703495 · Cited by 50
Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms
Wong, J. T., & Long, A. A. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.004 · Cited by 51
Functional Characterization of CD11c+ Age-Associated B Cells as Memory B Cells
Du, S. W., Arkatkar, T., Qureshah, F. A. A., Jacobs, H. M., Thouvenel, C. D., Chiang, K., Largent, A. D., Li, Q., Hou, B., Rawlings, D. J., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900404 · Cited by 53
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology
Gresham, L. M., Marzario, B., Dutz, J. P., & Kirchhof, M. G. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.047 · Cited by 49
Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study
Feuchtenberger, M., Kleinert, S., Schwab, S., Roll, P., Scharbatke, E., Ostermeier, E., Voll, R. E., Schäfer, A., & Tony, H. (2011) · Rheumatology International · doi:10.1007/s00296-011-1808-z · Cited by 47
The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease: Table 1.
Vandecasteele, S. J., Ombelet, S., Blumental, S., & Peetermans, W. E. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv030 · Cited by 48
S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Schirmer, J. H., & Moosig, F. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0393-2 · Cited by 46
Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity?
Salemi, S., & D’Amelio, R. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.483028 · Cited by 45
Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
Winthrop, K. L., Saag, K. G., Cascino, M. D., Pei, J., John, A. K., Jahreis, A., Haselkorn, T., & Furst, D. E. (2018) · Arthritis Care & Research · doi:10.1002/acr.23781 · Cited by 45
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
Yan, Z., Yang, M., & Lai, C. (2021) · Vaccines · doi:10.3390/vaccines9101097 · Cited by 48
Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy
Kado, R., Sanders, G., & McCune, W. J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000377 · Cited by 44
Pneumococcal polysaccharide vaccines
Jackson, L. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00033-1 · Cited by 43
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
Cohen, D., Krauthammer, S. H., Cohen, Y. C., Perry, C., Avivi, I. M., Herishanu, Y., & Even‐Sapir, E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05389-x · Cited by 43
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis
Lan, L., Han, F., & Chen, J. (2012) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1200057 · Cited by 42
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
King, C., & Harper, L. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0082-y · Cited by 42
Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants
Gomez, E. V., Bishop, J. L., Jackson, K. A., Muram, T. M., & Phillips, D. L. (2017) · BioDrugs · doi:10.1007/s40259-017-0249-y · Cited by 41
Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases
Papadopoulou, D., & Sipsas, N. V. (2013) · Rheumatology International · doi:10.1007/s00296-013-2907-9 · Cited by 40
Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial
Nguyen, M., Lindegaard, H., Hendricks, O., Jørgensen, C. S., Kantsø, B., & Friis‐Møller, N. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161407 · Cited by 40
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases
McMahan, Z. H., & Bingham, C. O. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0506-0 · Cited by 40
Self-citation
A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review
Soy, M., Keser, G., Atagündüz, P., Mutlu, M. Y., Gündüz, A., Köybaşı, G., & Beş, C. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05700-z · Cited by 39
Vaccinations for Rheumatoid Arthritis
Perry, L., Winthrop, K. L., & Curtis, J. R. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0431-x · Cited by 39
Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy
Intongkam, S., Samakkarnthai, P., Pakchotanon, R., Narongroeknawin, P., Asavatanabodee, P., & Chaiamnuay, S. (2018) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000877 · Cited by 39
Regulation of CD8 T cell by B-cells: A narrative review
Meerhaeghe, T. V., Néel, A., Brouard, S., & Degauque, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125605 · Cited by 42
From mechanism to therapies in systemic lupus erythematosus
Paley, M., Strand, V., & Kim, A. H. J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000369 · Cited by 38
T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Winthrop, K. L., Korman, N. J., Abramovits, W., Rottinghaus, S. T., Tan, H., Gardner, A., Mukwaya, G., Kaur, M., & Valdez, H. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.076 · Cited by 35
Outcome Measures in Acute Gout: A Systematic Literature Review
Dalbeth, N., Zhong, C. S., Grainger, R., Khanna, D., Khanna, P. P., Singh, J. A., McQueen, F. M., & Taylor, W. J. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.131244 · Cited by 34
Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases
Yun, H., Xie, F., Baddley, J. W., Winthrop, K. L., Saag, K. G., & Curtis, J. R. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160685 · Cited by 34
To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis
Zhou, Q., Zhou, R., Yang, H., & Yang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733418 · Cited by 34
Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica
Mahmood, N. A., Silver, K. M., Onel, K. B., Ko, M., & Javed, A. (2010) · Journal of Child Neurology · doi:10.1177/0883073810381445 · Cited by 32
In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles
Pozsgay, J., Babos, F., Uray, K., Magyar, A., Gyulai, G., Kiss, É., Nagy, G., Rojkovich, B., Hudecz, F., & Sármay, G. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0918-0 · Cited by 33
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study
Kridin, K., Mruwat, N., Amber, K. T., & Ludwig, R. J. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljac118 · Cited by 32
Influenza and pneumococcal vaccination in patients with rheumatoid arthritis in comparison with age- and sex-matched controls: results of a claims data analysis
Ramos, A. L., Hoffmann, F., Callhoff, J., Zink, A., & Albrecht, K. (2016) · Rheumatology International · doi:10.1007/s00296-016-3516-1 · Cited by 32
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
Emery, P., Furst, D. E., Kirchner, P., Melega, S., Lacey, S., & Lehane, P. B. (2019) · Rheumatology and Therapy · doi:10.1007/s40744-019-00183-6 · Cited by 32
Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab
Furer, V., Zisman, D., Kaufman, I., Arad, U., Berman, M., Sarbagil‐Maman, H., Elias, M., Haddad, A., Paran, D., Drori, Y., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.10.081 · Cited by 32
Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters
Magliulo, D., Wade, S. D., & Kyttaris, V. C. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108897 · Cited by 33
Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis
Garrido, H. M. G., Veurink, A. M., Leeflang, M., Spijker, R., Goorhuis, A., & Grobusch, M. P. (2019) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2019.101479 · Cited by 31
Possible therapeutic agents for COVID-19: a comprehensive review
Elhusseiny, K. M., Abd‐Elhay, F. A., & Kamel, M. G. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1782742 · Cited by 31
2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis
Brenol, C. V., da Mota, L. M. H., Cruz, B. A., Pileggi, G. S., Pereira, I. A., Rezende, L. S., Bértolo, M. B., Freitas, M. V. C., da Silva, N. A., Louzada‐Júnior, P., et al. (2013) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/s2255-5021(13)70002-6 · Cited by 30
The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults
Day, A. L., Winthrop, K. L., & Curtis, J. R. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20056 · Cited by 32
Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases
Broyde, A., Arad, U., Madar-Balakirski, N., Paran, D., Kaufman, I., Levartovsky, D., Wigler, I., Caspi, D., & Elkayam, O. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150397 · Cited by 30
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study
Bühler, S., Jaeger, V. K., Adler, S., Bannert, B., Brümmerhoff, C., Ciurea, A., Distler, O., Franz, J. K., Gabay, C., Hagenbuch, N., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez045 · Cited by 29
Secondary Hypogammaglobulinemia
Kaplan, B. M., & Bonagura, V. R. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.08.005 · Cited by 29
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
Tolf, A., Wiberg, A., Müller, M., Nazir, F. H., Pavlović, I., Laurén, I., Mangsbo, S. M., & Burman, J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11497 · Cited by 32
First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
Ye, Y., Gaudy, A. M., Schafer, P. H., Thomas, M. A., Weiss, D., Chen, N., Liu, L., Xue, Y., Carayannopoulos, L. N., & Palmisano, M. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.869 · Cited by 27
Current Take on Systemic Sclerosis Patients’ Vaccination Recommendations
Murdaca, G., Noberasco, G., Olobardi, D., Lunardi, C., Maule, M., Delfino, L., Triggiani, M., Cardamone, C., Benfaremo, D., Moroncini, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9121426 · Cited by 28
Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review
Garcillán, B., Salavert, M., Regueiro, J. R., & Díaz-Castroverde, S. (2022) · Vaccines · doi:10.3390/vaccines10020297 · Cited by 28
Vaccines and biologics
Ferreira, I., & Isenberg, D. A. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205246 · Cited by 29
On the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 27
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Park, E.-J., Kim, H., Jung, S., Sung, Y.-K., Baek, H., & Lee, J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.411 · Cited by 39
Multiple sclerosis and COVID‐19: The Swedish experience
Landtblom, A., Berntsson, S. G., Boström, I., & Iacobaeus, E. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13453 · Cited by 26
Impfung bei erwachsenen Patienten mit chronisch entzündlichen rheumatischen Erkrankungen
der DGRh, K. P., Goldacker, S., Gause, A., & Warnatz, K. (2013) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-013-1155-4 · Cited by 25
Emerging drugs to treat juvenile idiopathic arthritis
Ruperto, N., & Martini, A. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.581662 · Cited by 25
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
Hill, J. A., Kiem, E. S., Bhatti, A., Liu, W. L., Keane-Candib, J., Fitzpatrick, K. S., Boonyaratanakornkit, J. B., Gardner, R., Green, D. J., Maloney, D. G., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.001 · Cited by 25
Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis
Niles, J. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04363.x · Cited by 25
Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis
Bluett, J., Jani, M., & Symmons, D. P. M. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0071-5 · Cited by 24
Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy
Bemben, N. M., & Berg, M. L. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2671 · Cited by 24
Vaccination in the Era of Immunosuppression
Alnaimat, F., Sweis, J. J. G., Jansz, J., Modi, Z. N., Prasad, S., AbuHelal, A., Vagts, C. L., Hanson, H. A., Ascoli, C., Novak, R. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11091446 · Cited by 30
Initial Management of Rheumatoid Arthritis
Gramling, A., & O’Dell, J. R. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.05.003 · Cited by 24
Vaccination recommendations for patients with neuromuscular disease
Esposito, S., Bruno, C., Berardinelli, A. L., Filosto, M., Mongini, T., Morandi, L. O., Musumeci, O., Pegoraro, E., Siciliano, G., Tonin, P., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.003 · Cited by 24
Vaccinations for rheumatoid arthritis
Friedman, M., & Winthrop, K. L. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000281 · Cited by 24
Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Silva-Fernández, L., Cock, D. D., Lunt, M., Low, A., Watson, K. D., BSRBR-RA Contributors Group, Symmons, D. P. M., & Hyrich, K. L. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex304 · Cited by 24
SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study
Shields, A. M., Venkatachalam, S., Shafeek, S., Paneesha, S., Ford, M., Sheeran, T. P., Kelly, M., Qureshi, I., Salhan, B., Karim, F., et al. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab018 · Cited by 23
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Park, E.-J., Kim, H., Jung, S. M., Sung, Y., Baek, H. J., & Lee, J. (2020) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2020.27.1.4 · Cited by 23
30 Years of Biotherapeutics Development—What Have We Learned?
Ghilardi, N., Pappu, R., Arron, J. R., & Chan, A. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101619-031510 · Cited by 24
Are autoantibodies the targets of B-cell-directed therapy?
Pisetsky, D. S., Grammer, A. C., Ning, T. C., & Lipsky, P. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.108 · Cited by 23
Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases
Fitzgerald, K. C., Mecoli, C. A., Douglas, M., Harris, S., Aravidis, B., Albayda, J., Sotirchos, E. S., Höke, A., Orbai, A., Petri, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab407 · Cited by 23
Self-citation
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis
Simader, E., Tobudic, S., Mandl, P., Haslacher, H., Perkmann, T., Nothnagl, T., Sautner, J., Radner, H., Winkler, F., Burgmann, H., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221347 · Cited by 21
B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use
Yusof, M. Y. M., Vital, E. M. J., & Buch, M. H. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0539-7 · Cited by 22
B cell therapies for rheumatoid arthritis: beyond B cell depletion.
Calero, I., Nieto, J., & Sanz, I. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.02.003 · Cited by 22

Authors: Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A.
Affiliations: Johns Hopkins University (US)
University of Rochester (US)
Oregon Health & Science University (US)
Genentech (US)
ORCID: Bingham, Clifton O.
Deodhar, Atul
Greenwald, Maria
Agarwal, Sunil
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2009-12-28
Volume: 62
Issue: 1
Pages: 64-74
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.25034
OpenAlex: W2042927558
Cited by: 459
References: 37
Citations by year: 2026: 12 · 2025: 14 · 2024: 15 · 2023: 27 · 2022: 33 · 2021: 64 · 2020: 33 · 2019: 23 · 2018: 22 · 2017: 35 · 2016: 21 · 2015: 29 · 2014: 28 · 2013: 34 · 2012: 23
FWCI: 16.04
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: rheumatoid arthritis, rituximab, immunization response, vaccine immunogenicity, tetanus toxoid vaccine, pneumococcal polysaccharide vaccine, keyhole limpet hemocyanin, delayed-type hypersensitivity, methotrexate, T cell-independent response
MeSH terms: Rituximab, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antibody Formation, Arthritis, Rheumatoid, Drug Therapy, Combination, Female, Hemocyanins, Humans, Hypersensitivity, Delayed, Immunologic Memory, Influenza Vaccines, Lymphocyte Depletion, Male, Methotrexate, Middle Aged, Skin Tests, Tetanus Toxoid, Vaccines, B-Lymphocyte Subsets, Antirheumatic Agents, Lymphocyte Count, Antigens, CD20, Pneumococcal Vaccines, Young Adult, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks